Advocacy

ASAM serves its members in many ways. One of the most important ways is by helping to play an active role in shaping government policies that affect their livelihoods and the livelihoods of their patients.

ASAM advocates for policies that promote access to high-quality treatment and recovery support services for the 22 million Americans who suffer from a substance use disorder. The information here will help you stay up to date on emerging issues, enable you to take action and become an advocate for your patients and your practice, and learn about how ASAM is working with government, insurers and other national organizations to promote policies that advance addiction medicine.

CSOO

Opioid misuse and overdose are a public health crisis in the United States.  The American Society of Addiction Medicine (ASAM) and others have come together as the Coalition to Stop Opioid Overdose to advance meaningful legislative and regulatory policies this year in response to the opioid epidemic.

2016 NPF Training_472x176 

2016 NPF Training

Audio, text, slides, photos and selected 5-minute videos segments from the 2016 NPF/ ASAM Training held in April 2016 preceding the 47th ASAM Annual Conference in Baltimore, MD.

Events_472x176

Advocacy Events

Sign up to participate in advocacy events and learn about the latest happenings on Capitol Hill.

Advocacy Events_472x176

Advocacy Issues

Find the latest information on issues of importance to the field of addiction medicine.

NPF training_472x176

Advocacy News

News and information about ASAM Advocacy.

Find a Policy Statement_472x176

Find a Policy Statement

Learn about ASAM's position on current policy issues.

Advocacy Toolkits_472x176

Advocacy Toolkits

Access resources that will equip you to advocate effectively for policies that promote addiction treatment and prevention.

Staff

Kelly Corredor
Director, Advocacy and Government Relations
kcorredor@ASAM.org | .301.547.4111

 

Susan Awad
Policy Advisor
sawad@ASAM.org | .301.547.4103

 

Corey Barton
Manager, Private Sector Relations
cbarton@ASAM.org | 301.547.4106

 

Brad Bachman
Manager, State Government Relations
bbachman@ASAM.org | 301.547.4107

 

Connor Galvin
Coordinator, Advocacy, Policy and Payer Relations
cgalvin@ASAM.org | 301.547.4135

Committee Chairs

Corey Waller, MD, MS, FACEP
Flora Sadri, DO, MPF, FAAFP

Chair and Vice Chair, Legislative Advocacy Committee

 

Jeffrey Selzer, MD, DFASAM
Randolph Holmes, MD, FASAM

Chair and Vice Chair, Public Policy Committee

 

Shawn Ryan, MD, MBA, FASAM
Frank James, MD, JD

Chair and Vice Chair, Payer Relations Committee

ASAM commends the President’s commission for a thorough and thoughtful report that recommends an array of smart and actionable interventions

by ASAM Staff | Nov 02, 2017

Rockville, MD - Yesterday, President Trump’s Commission on Combating Drug Addiction and the Opioid Epidemic held its fifth and final meeting during which the commission approved its final report to the president. The president established the commission to review the state of drug addiction and the opioid epidemic in the United States and to make recommendations regarding how the Federal Government can best address this crisis.

ASAM commends the president’s commission for a thorough and thoughtful report that recommends an array of smart and actionable interventions that can make a meaningful difference in our nation’s current opioid epidemic. ASAM submitted comments to the commission in preparation for the report and is glad that many of those recommendations are incorporated in the final report, including:

  • The development and implementation of a national public education campaign to reduce addiction stigma;
  • Training prescribers in engagement and addiction screening strategies to identify substance use disorders and link patients to treatment;
  • Requiring that clinicians registered with the DEA to prescribe controlled substances demonstrate competency in opioid prescribing;
  • Improving the quality of treatment by, among other things, using The ASAM Criteria to help determine the appropriate level of care and services needed by patients;
  • The systematic monitoring and enforcement of the Mental Health Parity and Addiction Equity Act (MHPAEA) to ensure parity in the coverage of mental health and addiction services; and
  • Ensuring there are adequate resources for a sufficient and well-trained workforce of addiction specialist physicians and other clinicians.

Dr. Kelly Clark, MD, MBA, DFASAM, president of ASAM, had this to say about the commission’s report:

“The commission clearly considered the evidence for what works in addiction prevention, treatment, and recovery. That focus on the scientific understanding of addiction as a chronic, relapsing brain disease that can be successfully treated with evidence-based solutions should be carried through by the administration and Congress as they consider and implement the commission’s recommendations. ASAM urges our federal, state, and local elected leaders to take the commission’s report to heart and work quickly. ASAM stands ready to work with the administration and Congress to mount a united response to this public health emergency which must include sufficient funds to implement the commission’s recommendations.”

###

Advocacy Articles

ASAM commends the President’s commission for a thorough and thoughtful report that recommends an array of smart and actionable interventions

by ASAM Staff | Nov 02, 2017

Rockville, MD - Yesterday, President Trump’s Commission on Combating Drug Addiction and the Opioid Epidemic held its fifth and final meeting during which the commission approved its final report to the president. The president established the commission to review the state of drug addiction and the opioid epidemic in the United States and to make recommendations regarding how the Federal Government can best address this crisis.

ASAM commends the president’s commission for a thorough and thoughtful report that recommends an array of smart and actionable interventions that can make a meaningful difference in our nation’s current opioid epidemic. ASAM submitted comments to the commission in preparation for the report and is glad that many of those recommendations are incorporated in the final report, including:

  • The development and implementation of a national public education campaign to reduce addiction stigma;
  • Training prescribers in engagement and addiction screening strategies to identify substance use disorders and link patients to treatment;
  • Requiring that clinicians registered with the DEA to prescribe controlled substances demonstrate competency in opioid prescribing;
  • Improving the quality of treatment by, among other things, using The ASAM Criteria to help determine the appropriate level of care and services needed by patients;
  • The systematic monitoring and enforcement of the Mental Health Parity and Addiction Equity Act (MHPAEA) to ensure parity in the coverage of mental health and addiction services; and
  • Ensuring there are adequate resources for a sufficient and well-trained workforce of addiction specialist physicians and other clinicians.

Dr. Kelly Clark, MD, MBA, DFASAM, president of ASAM, had this to say about the commission’s report:

“The commission clearly considered the evidence for what works in addiction prevention, treatment, and recovery. That focus on the scientific understanding of addiction as a chronic, relapsing brain disease that can be successfully treated with evidence-based solutions should be carried through by the administration and Congress as they consider and implement the commission’s recommendations. ASAM urges our federal, state, and local elected leaders to take the commission’s report to heart and work quickly. ASAM stands ready to work with the administration and Congress to mount a united response to this public health emergency which must include sufficient funds to implement the commission’s recommendations.”

###